Jayanthi Lea, M.D.

Dr. Jayanthi Lea is the DIvision Chief of Gynecologic Oncology and the Director of the Gynecologic Oncology Fellowship Program, in the Department of Obstetrics and Gynecology at UT Southwestern.

Board certified both in gynecologic oncology and in obstetrics and gynecology, Dr. Lea is skilled in radical surgical procedures for gynecologic cancers, including cytoreductive surgery for ovarian/ fallopian tube cancers, radical pelvic surgery and minimally invasive, robotic surgery and advanced laparoscopic surgery. Dr. Lea is the Disease Oriented Team Leader for Gynecologic Oncology at the Harold C. Simmons Comprehensive Cancer Center and utilizes a team approach to coordinate and provide comprehensive patient care. She is also the physician champion for the Gynecologic Oncology Previvor Program. Dr. Lea is committed to supporting patients facing gynecologic cancers through every step of their cancer journey, from diagnosis to treatment and beyond.

Dr. Lea is dedicated to advancing the field of gynecologic oncology through research and education.  She is a member of the National Cancer Institute’s NRG Oncology and Gynecologic Oncology Group (GOG) Foundation/ Partners and serves on the ovarian, cervical and developmental therapeutics subcommittees.

Dr. Lea graduated from the University of North Carolina at Chapel Hill with a bachelors of science degree in biology. She received her medical degree from East Carolina University School of Medicine and completed her residency training in obstetrics and gynecology at Riverside Methodist Hospital in Columbus, Ohio. Following a four-year gynecologic oncology fellowship at UT Southwestern Medical Center, she joined the faculty here as a scholar of the NIH Reproductive Scientist Development Program.  Dr. Lea investigated the molecular pathogenesis of cervical cancer. Her clinical research interests are in the development of clinical trials for ovarian and cervical cancers using novel therapeutic agents and her basic research interest is in early detection methods for ovarian cancer. She has published several peer reviewed manuscripts on cervical, endometrial and ovarian cancers as well as quality improvement studies in gynecologic oncology. 

Medical School

East Carolina University (1996)

Internship

Riverside Methodist Hospital (1997), Obstetrics & Gynecology

Residency

Riverside Methodist Hospital (2000), Obstetrics & Gynecology

Fellowship

UT Southwestern Medical Center (2004), Gynecologic Oncology

• Cervical Cancer
• Developmental Therapeutics
• Ovarian Cancer

Featured Publications

Oxygenation in cervical cancer and normal uterine cervix assessed using blood oxygenation level-dependent (BOLD) MRI at 3T.

Hallac RR, Ding Y, Yuan Q, McColl RW, Lea J, Sims RD, Weatherall PT, Mason RP NMR Biomed 2012 Dec 25 12 1321-30

Lymph node metastasis in endometrioid adenocarcinomas of the uterine corpus with occult cervical involvement.

Boren T, Lea J, Kehoe S, Miller DS, Richardson D Gynecol. Oncol. 2012 Oct 127 1 43-6

Cervical cancer.

Lea JS, Lin KY Obstet. Gynecol. Clin. North Am. 2012 Jun 39 2 233-53

Correlation of cone biopsy with findings at radical hysterectomy and use of adjuvant radiation therapy.

Boren TP, Carrick K, Kehoe SM, Lea J, Miller DS, Richardson DL Gynecol. Oncol. 2012 Mar 124 3 508-11

Silencing of HPV 18 Oncoproteins with RNA Interference Causes Growth Inhibition of Cervical Cancer Cells.

Lea JS, Sunaga N, Sato M, Kalahasti G, Burbee DG, Minna JD, Muller CY Reproductive Sciences. January 2007 Vol. 14, No.1 20-28

Adenosquamous Histology Predicts Poor Outcome

Lea JS, Coleman RL, Garner EO, Duska LR, Miller DS, Schorge JO Gynecologic Oncology 2003 91:558-62

Cervical Adenocarcinoma in situ in Women Younger than Forty Years

Lea JS, Shin CH, Sheets EE, Gehrig PA, Coleman RL, Duska LR, Miller DS, Schorge JO Gynecologic Oncology 2002 87:129-132

Stage IIB-IVB Cervical Adenocarcinoma: Prognostic Factors and Survival

Lea JS, Wenham RM, Sheets EE, Duska LR, Coleman RL, Miller DS, Schorge JO Gynecologic Oncology 2002 84:115-9

The Role of Para-Aortic Lymph Node Dissection in Early Stage Cervical Adenocarcinoma

Lea JS, Sheets EE, Duska LR, Miller DS, Coleman RL, Muller CY, Schorge JO Gynecologic Oncology 2002 285:288

Secondary Cytoreductive Surgery for Platinum Sensitive Ovarian Cancer

Schorge JO, Wingo SN, Bhore R, Hefferenan TP, Lea JS Int. Journal of Gynecology and Obstetrics November 2009

• Alpha Omega Alpha Honor Society
  (2023)
• Best Doctors in Dallas
  (2018)
• Texas Super Doctors
  (2017)
• Texas Super Doctors 2017, 2018
  Texas Monthly (2017-2018)
• Best Doctors in America
  (2009)
• Best Doctors in North Carolina
  (2009)
• Best in Category Research Award
  American College of Obstetrics and Gynecology Clinical Meeting (2007)
• Fellow
  American College of Obstetrics and Gynecology (2006)
• Reproductive Scientist Development Program Scholar
  NIH K12 Award (2006)

• American College of Obstetrics and Gynecology
• American College of Surgeons (2017)
• American Society of Clinical Oncology
• Gynecologic Oncology Group
• NRG Oncology (2015)
• Society of Gynecologic Oncology